Post-exposure treatment of Ebola virus using passive immunotherapy: Proposal for a new strategy
Citation: Chippaux J-P., Boyer L.P and Alagon A. Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy. Journal of Venomous Animals and Toxins including Tropical Diseases 2015:21(3).
Summary: A systematic review (no details given) was undertaken on the use of passive immunotherapy for the treatment or prevention of Ebola virus disease (EVD). Comparing the use of passive therapy currently used for venom-induced disease, it is stated that hyperimmune equine IgG fragments and purified polyclonal whole IgG deserve further consideration as treatment for exposure to Ebola virus.
Experimental treatment with monoclonal antibodies is not a widely available treatment for Ebola infection but a model similar to the use of antivenom treatments is now possible through developments in the use of immunoglobulin G (IgG) and increased understanding of pharmacokinetics. Equine polyclonal IgG fragments are more suited to the political, social and economic constraints of African countries. Convalescent human plasma is considered difficult and dangerous to collect and administer. Details are given of seven steps towards the development of treatment of people exposed to the Ebola virus or affected by EVD.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on Ebola but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about Ebola on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.